References
  1. Matuk-Villazon O, Roberts JC, Corrales-Medina FF, Hemophilia: The Past, the Present, and the Future, Pediatr Rev. 2021 Dec 1;42(12):672-683.
  2. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia.2020;26(Suppl 6):1–158.
  3. Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. N Engl J Med 2020;383:1018-1027.
  4. Bioverativ Therapeutics Inc. Efanesoctocog alfa [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl]: US prescribing information. 2023.
  5. Malec L, Peyvandi F, Chan AKC, et al; for the XTEND-Kids Trial Group. Efanesoctocog alfa prophylaxis for previously treated patients <12 years of age with severe hemophilia A. ISTH 2023 Congress; June 24-28, 2023. Abstract LB01.1.
  6. Pipe S, Sadeghi‐Khomami A, Konkle BA, Kitchen S, Negrier C, Liu M, Santagostino E, Willemze A, Abad‐Franch L, Knobe K, Seth Chhabra E. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one‐stage clotting and chromogenic substrate assays at clinical haemostasis laboratories. Haemophilia. 2023 Oct 30. doi: 10.1111/hae.14831. Online ahead of print.